Medical University Of Vienna
- Address
- lock Available on a paid plan
HER3‑Targeted Antibody‑Drug Conjugate Research
The division focuses on evaluating a novel HER3‑DXd in patients with advanced cancers that have spread to the central nervous system.
- Intracranial objective response assessment
- Overall survival analysis in leptomeningeal disease
- HER3 expression as a therapeutic target
The studies are conducted at Medical University of Vienna with strong collaboration between academic investigators and commercial partners.
Central Nervous System Metastasis Trials
Clinical investigations address brain metastases arising from Metastatic Breast Cancer and Non‑Small Cell Lung Cancer, aiming to improve treatment outcomes inside the skull.
- Use of Response Assessment in Neuro‑Oncology Brain Metastases (RANO‑BM) criteria
- Evaluation of intracranial objective response rate
- Multi‑cohort design to compare different tumor origins
Over 184 investigators contribute to these trials, reflecting the site’s extensive expertise in neuro‑oncology.
Leptomeningeal Carcinomatosis Studies
A dedicated cohort investigates patients with solid tumors and untreated leptomeningeal disease, testing whether the HER3‑conjugate can extend survival.
- Assessment of three‑month overall survival
- Safety monitoring in the spinal and cranial CSF compartments
- Biomarker analysis of HER3 expression in leptomeningeal cells
The program highlights the department’s commitment to tackling rare and aggressive CNS complications of cancer.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 34 therapeutic areas and 15 of 800 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 763 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 145 by active trials.
- 1Medical University Of Vienna69active
lock +144 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Medical University Of Vienna85trials
lock +86 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 152 other sites in Austria
Therapeutic Area Benchmark — Austria
Select a therapeutic area to compare against other sites in Austria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Austria
Market Share
Country: Austria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medical University Of Vienna
lock Showing 1 of 667 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21466) A multicenter, randomized, double-blind, placebo-controlled, Phase 3 study to investigate the efficacy, safety, and PK/ PD of finerenone, in addition to standard-of-care, in pediatric patients, 6 months to < 18 years of age, with heart failure (HF) and left ventricular systolic dysfunction (LVSD) | Bayer AG | Phase III | Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 800 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 30 | Unknown | 2016-11-17 | 2026-07-09 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.